Disulfiram for Treating Cocaine Dependence in Individuals Maintained on Methadone

Overview

Cocaine is an extremely addictive stimulant drug that directly affects the brain. It is used in several different forms and can be snorted, smoked, or injected to achieve the desired effect. Cocaine users are at risk for many health problems, both directly and indirectly related to the effects of cocaine. Disulfiram, a drug used to treat chronic alcoholism, may be effective in reducing cocaine use. This study will evaluate the effectiveness of three different doses of disulfiram in treating cocaine dependence in opioid- and cocaine-dependent individuals maintained on methadone.

Full Title of Study: “Disulfiram for Cocaine Abuse in Methadone- Patients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: January 2007

Detailed Description

Despite the harm that cocaine can cause to the body, its abuse is widespread. It is the cause of more visits to hospital emergency rooms nationwide than any other illegal drug. Effective treatments for cocaine and opiate addictions are essential to the decline of cocaine- and opiate-related disorders. Unfortunately, cocaine use remains prevalent among participants in many opioid maintenance programs. The addition of other medications to methadone maintenance may prove helpful in reducing cocaine use. Disulfiram, a drug used to treat chronic alcoholism, causes unpleasant effects when even small amounts of alcohol are consumed. This study will evaluate the effectiveness of three different doses of disulfiram in treating cocaine dependence in opioid- and cocaine-dependent individuals maintained on methadone. Participants in this double blind study will be randomly assigned to receive either disulfiram at one of three dosage levels (62.5, 125, 250 mg/day) or placebo for 14 weeks. During the first 2 weeks, doses of methadone plus either disulfiram or placebo will be administered until the assigned maintenance dose is achieved. This dosage level will be maintained for the duration of the study. Participants will be required to report to the study site Monday through Saturday of each week for assessments and to receive medication. They will receive a take-home dose of medication for Sunday. In addition, participants will receive a weekly session of cognitive-behavioral therapy. Urine samples will be collected three times a week to assess drug use. At the end of the study, participants will undergo a 4- to 6-week detoxification period in which they will gradually discontinue the use of methadone and disulfiram. All participants have the option to request transfer to a local methadone maintenance program instead of undergoing detoxification. Enrollment has been completed and no subjects are active. Data analyses are being conducted at this time.

Interventions

  • Drug: Disulfiram
    • Disulfiram at 0, 62.5, 125 and 250 mg/day were administered during weeks 3-14

Arms, Groups and Cohorts

  • Placebo Comparator: Placebo
    • Placebo (microcrystalline cellulose) was suspended in the methadone during weeks 3-14.
  • Active Comparator: Disulfiram at 62.5 mg
    • Disulfiram at 62.5 mg was suspended in the methadone during weeks 3-14.
  • Active Comparator: Disulfiram at 125 mg
    • Disulfiram at 125 mg/day was suspended in methadone during weeks 3-14.
  • Active Comparator: Disulfiram at 250 mg
    • Disulfiram at 250 mg/day was suspended in methadone during weeks 3-14.

Clinical Trial Outcome Measures

Primary Measures

  • Cocaine use
    • Time Frame: 14 wks
    • Urine toxicology screens were conducted thrice-weekly for 14 weeks.

Participating in This Clinical Trial

Inclusion Criteria

  • History of cocaine use at least once a week during the month prior to study entry – Urine screen tests positive for cocaine – Meets DSM-IV criteria for opioid- and cocaine-dependence – Urine toxicology screen tests negative for benzodiazepines prior to beginning methadone treatment Exclusion Criteria:

  • Current drug or alcohol dependence other than opiates, cocaine, or tobacco – Significant medical condition, such as abnormal liver function (with laboratory findings greater than three times normal), active hepatitis, or high blood pressure – Current cardiac condition – Occult coronary artery disease – At high risk for cardiovascular disease, seizure disorders, or any other significant underlying medical condition that may make treatment with disulfiram or methadone unsafe – Meets DSM-IV psychiatric diagnostic criteria for lifetime schizophrenia, bipolar disorder, or other psychotic disorders – Currently suicidal or homicidal – Currently taking a prescribed psychotropic medication that cannot be discontinued – Pregnant – Currently taking metronidazole or clotrimazole

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Arkansas
  • Collaborator
    • Yale University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Alison Oliveto, PhD, Principal Investigator, UAMS

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.